Blueprint May Corner EGFR Exon Mutated Lung Cancer Market With Lengo Buyout

Lengo’s preclinical LNG-451, along with Blueprint’s BLU-945 and BLU-701, could create a portfolio of therapies covering 97% of non-small cell lung cancer cases involving EGFR exon mutations.